Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Yamamoto
Mio
M
Kuroda
Junya
J
Uchiyama
Hitoji
H
Kobayashi
Tsutomu
T
Tsutsumi
Yasuhiko
Y
Ohshiro
Muneo
M
Sasaki
Nana
N
Shimura
Yuji
Y
Mizutani
Shinsuke
S
Matsumoto
Yosuke
Y
Shimazaki
Chihiro
C
Horiike
Shigeo
S
Taniwaki
Masafumi
M
Shimazaki
Chihiro
C
D000208:Acute Disease; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D000069439:Dasatinib; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007938:Leukemia / Q000235:genetics / Q000628:therapy*; D008297:Male; D010677:Philadelphia Chromosome; D011743:Pyrimidines / Q000008:administration & dosage*; D013844:Thiazoles / Q000008:administration & dosage*; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D007166:Immunosuppressive Agents; D011743:Pyrimidines; D013844:Thiazoles; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine; D000069439:Dasatinib